Orgenesis Inc (ORGS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Orgenesis Inc (ORGS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9419
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Orgenesis Inc (Orgenesis) is a biopharmaceutical company that focuses on the development and manufacturing of regenerative cellular therapy and medicine for the treatment of insulin-dependent diabetes patients. The company, through its subsidiaries, offers contract development and manufacturing, and proprietary cell therapy development. It also provides GMP manufacturing, process development, quality management and assay development, and other services. Orgenesis offers cell therapies for autoimmune, oncologic, neurologic and orthopedic diseases. The company utilizes its proprietary technology to reprogram human liver cells into glucose-responsive insulin-producing cells to provide a practical cure for insulin-dependent diabetes. Orgenesis is headquartered in Germantown, Maryland, the US.

Orgenesis Inc (ORGS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orgenesis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Orgenesis Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Orgenesis Raises USD1.2 Million in Venture Financing 12
Orgenesis Raises USD5.3 Million in Financing Round 13
Partnerships 14
Zelluna Immunotherapy Enters into Partnership with Masthercell 14
CRISPR Therapeutics Enters into Agreement with MaSTherCell 15
Les Laboratoires Servier and Masthercell Enter into Agreement 16
Orgenesis Forms Joint Venture with Atvio Biotech 17
Orgenesis Forms Joint Venture with CureCell 18
Orgenesis Enters into Agreement with Biosequel 19
Orgenesis Enters into Research Agreement with GSRAC 20
Masthercell Forms Joint Venture with Kalon 21
Licensing Agreements 22
Orgenesis Enters into Licensing Agreement with Hemogenyx-Cell 22
Orgenesis Enters into Licensing Agreement with Immugenyx 23
HekaBio Enters into Licensing Agreement with Orgenesis 24
Orgenesis Enters into Licensing Agreement with BGN Technologies and National Institute for Biotechnology in the Negev 25
Orgenesis Enters Into Licensing Agreement With Tel Hashomer Medical Research For Autologous Insulin Producing Cells Regeneration Technology 26
Equity Offering 27
Orgenesis Plans to Raise up to USD100 Million in Public Offering of Securities 27
Masthercell Raises USD5.9 Million in Equity Financing 28
Orgenesis Raises USD1 Million in Private Placement of Shares and Warrants 29
Orgenesis Raises USD4.3 Million in Private Placement of Shares and Warrants 30
Orgenesis Raises Funds through Private Placement of Shares and Warrants 31
Orgenesis Raises Funds through Private Placement of Shares and Warrants 32
Orgenesis Raises USD0.2 Million in Private Placement of Shares and Warrants 33
Orgenesis Announces Private Placement Of Shares For US$3 Million 34
Orgenesis Completes Private Placement Of Units For US$1.3 Million 35
Acquisition 36
Orgenesis Acquires MaSTherCell 36
Orgenesis Inc – Key Competitors 37
Orgenesis Inc – Key Employees 38
Orgenesis Inc – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Apr 19, 2018: Orgenesis Reports 42% Increase in Revenue for the First Quarter of Fiscal 2018 40
Government and Public Interest 42
Feb 13, 2017: Orgenesis Approved for Euro 12.3 Million European Grant for Further Development of Its Type 1 Diabetes Program 42
Other Significant Developments 43
Mar 08, 2017: Orgenesis Provides Update Regarding AIP Cell-Based Therapy for Type 1 Diabetes, MaSTherCell Cell Manufacturing Subsidiary and Overall Financial Condition 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Orgenesis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orgenesis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orgenesis Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Orgenesis Raises USD1.2 Million in Venture Financing 12
Orgenesis Raises USD5.3 Million in Financing Round 13
Zelluna Immunotherapy Enters into Partnership with Masthercell 14
CRISPR Therapeutics Enters into Agreement with MaSTherCell 15
Les Laboratoires Servier and Masthercell Enter into Agreement 16
Orgenesis Forms Joint Venture with Atvio Biotech 17
Orgenesis Forms Joint Venture with CureCell 18
Orgenesis Enters into Agreement with Biosequel 19
Orgenesis Enters into Research Agreement with GSRAC 20
Masthercell Forms Joint Venture with Kalon 21
Orgenesis Enters into Licensing Agreement with Hemogenyx-Cell 22
Orgenesis Enters into Licensing Agreement with Immugenyx 23
HekaBio Enters into Licensing Agreement with Orgenesis 24
Orgenesis Enters into Licensing Agreement with BGN Technologies and National Institute for Biotechnology in the Negev 25
Orgenesis Enters Into Licensing Agreement With Tel Hashomer Medical Research For Autologous Insulin Producing Cells Regeneration Technology 26
Orgenesis Plans to Raise up to USD100 Million in Public Offering of Securities 27
Masthercell Raises USD5.9 Million in Equity Financing 28
Orgenesis Raises USD1 Million in Private Placement of Shares and Warrants 29
Orgenesis Raises USD4.3 Million in Private Placement of Shares and Warrants 30
Orgenesis Raises Funds through Private Placement of Shares and Warrants 31
Orgenesis Raises Funds through Private Placement of Shares and Warrants 32
Orgenesis Raises USD0.2 Million in Private Placement of Shares and Warrants 33
Orgenesis Announces Private Placement Of Shares For US$3 Million 34
Orgenesis Completes Private Placement Of Units For US$1.3 Million 35
Orgenesis Acquires MaSTherCell 36
Orgenesis Inc, Key Competitors 37
Orgenesis Inc, Key Employees 38
Orgenesis Inc, Subsidiaries 39

List of Figures
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Orgenesis Inc (ORGS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ocugen Inc (OCGN):企業の財務・戦略的SWOT分析
    Summary Ocugen Inc (Ocugen), formerly Histogenics Corp, is a biopharmaceutical company that discovers, develops and commercializes transformative drugs for the treatment of eye diseases. The company’s lead product candidate, OCU300, is a small molecule therapeutic intended for the treatment of ocula …
  • Randall & Quilter Investment Holdings Ltd.:企業のM&A・事業提携・投資動向
    Randall & Quilter Investment Holdings Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Randall & Quilter Investment Holdings Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detai …
  • Auswide Bank Ltd (ABA):企業の財務・戦略的SWOT分析
    Auswide Bank Ltd (ABA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Uzma Bhd (UZMA):企業の財務・戦略的SWOT分析
    Summary Uzma Bhd (Uzma) is an oil and gas service and equipment company. The company provides integrated solutions to the upstream sector. It offers geoscience and petroleum engineering, laboratory solutions, drilling and well services, production operation and optimization, manpower consultancy and …
  • PROS Holdings Inc (PRO):企業の財務・戦略的SWOT分析
    Summary PROS Holdings Inc (PROS) is an information technology company that offers profitability management and optimization software solutions. The company's products include Selling PRO, Pricing PRO, Revenue PRO and Pros for CRM. Its Selling PRO software comprises e-commerce, Smart CPQ and Deal des …
  • Domainex Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Domainex Ltd (Domainex) is a drug discovery service company that offers drug discovery programmes against a wide range of drug targets. The company provides services such as molecular biology / cdh, protein expression, assays, fragment screening, virtual screening, computational chemistry, m …
  • Sagent Pharmaceuticals, Inc.:企業のM&A・事業提携・投資動向
    Sagent Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sagent Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Just Dial Ltd:企業の戦略・SWOT・財務情報
    Just Dial Ltd - Strategy, SWOT and Corporate Finance Report Summary Just Dial Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Pan Orient Energy Corp (POE):石油・ガス:M&Aディール及び事業提携情報
    Summary Pan Orient Energy Corp (POE) is an independent upstream oil and gas company. The company has interests in onshore oil and gas assets in Thailand and Indonesia. It also has interests in Andora Energy Corporation, which holds properties in Northern Alberta. Its assets in Thailand include Conce …
  • Sumatec Resources Bhd (SUMATEC):石油・ガス:M&Aディール及び事業提携情報
    Summary Sumatec Resources Bhd (Sumatec) is an oilfield service provider that offers of construction and drilling services to the oil and gas industry. The company’s services include engineering and construction for oil and gas facilities, oil and gas assets development, supply and management of onsh …
  • R1 RCM Inc (RCM):企業の財務・戦略的SWOT分析
    R1 RCM Inc (RCM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Quantum Corp (QTM):企業の財務・戦略的SWOT分析
    Summary Quantum Corp (Quantum) is a technology company that offers intelligent solutions for capturing, sharing and preserving digital assets over the data lifecycle. The company provides products such as stornext scale-out storage, stornext pro solutions, lattus extended online, Q-cloud archive, qu …
  • Bioneer Corp (064550):製薬・医療:M&Aディール及び事業提携情報
    Summary Bioneer Corp (Bioneer) is a molecular diagnostic company that develops and produces molecular research and molecular diagnostic products and instruments. The company’s major molecular research products include DNA/RNA amplification pre mixes, DNA/RNA preparation system, oligo synthesis and r …
  • FibroStatin SL:製薬・医療:M&Aディール及び事業提携情報
    Summary FibroStatin SL (FibroStatin) is a drug development company that focuses on the development of treatment candidates for drug resistant lung cancer and idiopathic pulmonary fibrosis. The company’s pipeline products include T12/FST12 for NSCLC, GPBP-Mab/FSM26 for idiopathic pulmonary fibrosis a …
  • Bush Industries Inc:企業の戦略・SWOT・財務分析
    Bush Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Bush Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Crown Castle International Corp (CCI):企業の財務・戦略的SWOT分析
    Crown Castle International Corp (CCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • NEX Group plc.:企業の戦略的SWOT分析
    NEX Group plc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Just Energy Group Inc. (JE)-エネルギー分野:企業M&A・提携分析
    Summary Just Energy Group Inc. (Just Energy) is a provider of energy management solutions. The company offers natural gas, electricity, solar energy, green energy and energy efficiency tools and products to customers. It serves consumer and commercial markets through fixed price contracts, variable- …
  • Mission Pharmacal Company:製薬・医療:M&Aディール及び事業提携情報
    Summary Mission Pharmacal Company (Mission Pharmacal) develops, manufactures and markets prescription, over-the-counter and dietary supplement products. It offers products for conditions related to women’s health, urology, pediatrics, and dermatology, among others. It also offers contract manufactur …
  • Prana Biotechnology Ltd (PBT)-製薬・医療分野:企業M&A・提携分析
    Summary Prana Biotechnology Ltd (Prana Biotech) is a pharmaceutical company that develops therapeutic drugs. The company is conducting research into Huntington disease, Alzheimer's disease, brain cancer, and other major age-related degenerative disorders. It is developing first-in-class therapies fo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆